HCPCS code J7190 – Human plasma-derived Factor VIII

Key takeaways

J7190 covers human plasma-derived Factor VIII only, so recombinant, porcine-sequence and FVIII/VWF complex products bill under other codes.

One IU administered is one billing unit, so a 1,050 IU dose goes on the claim as 1,050 units.

Medicare Part B pays ASP+6% per IU, updated quarterly, before the 2% sequestration reduction and patient coinsurance.

Claims for single-dose or single-use J7190 products need the JW or JZ modifier, required on Medicare claims since July 1, 2023.

State Medicaid programs and many commercial payers require the 11-digit NDC, and a wrong or stale NDC is a common technical denial.

HCPCS code J7190 bills human Factor VIII by the unit

HCPCS code J7190 describes “Factor VIII (antihemophilic factor, human), per IU.” It’s the Level II J-code the Centers for Medicare and Medicaid Services assigns to plasma-derived Factor VIII concentrates. Each international unit you administer is one billing unit.

The word that does the work is “human.” Recombinant Factor VIII, porcine-sequence Factor VIII and FVIII/VWF complexes all bill under other codes. Pick the wrong family and the claim fails before anyone reads the dose.

Only plasma-derived concentrates belong under J7190

J7190 applies to human plasma-derived Factor VIII concentrates given in a clinic, a hospital outpatient department or at home. Hemofil M and Koate are the usual examples. FVIII/VWF complexes such as Alphanate and Humate-P look similar on the shelf, but they bill under J7186 and J7187.

Most miscoding happens on the exclusion side. None of these belong under J7190:

• Recombinant Factor VIII products (Advate, Kogenate FS, Helixate FS, Recombinate, Nuwiq). Each bills under a recombinant code, either J7192 or a product-specific code.
• Extended half-life (EHL) recombinant products (Eloctate, Jivi, Esperoct, Altuviiio). These usually carry their own product-specific codes, not J7190.
• Porcine-sequence recombinant Factor VIII (Obizur). It bills as J7188.
• FVIII/VWF complexes (Alphanate, Humate-P). These bill under J7186 and J7187.
• Factor IX products. A different clotting factor family with its own J-codes.
• Emicizumab (Hemlibra). A bispecific antibody, not a Factor VIII concentrate, so it bills separately.

The quickest check is the product source printed on the vial label, and the chart below maps each source to its code.

One IU administered equals one billing unit

J7190 is billed per IU of Factor VIII administered. The units on the claim equal the total IUs given in the session, not the number of vials opened.

The prescriber usually sets the dose with the standard weight-based formula for hemophilia A:

Target IU = Body weight (kg) x Desired factor rise (%) x 0.5

The formula sets the order, but the administration record sets the claim. If the record shows 2,500 IU given, you bill 2,500 units of J7190.

Vials rarely match a dose exactly, so the provider rounds up to the nearest available vial. The amount given goes on the claim. Any product left in an opened vial is wastage, reported with the JW modifier covered below.

J7190 vs J7188: Human Factor VIII or porcine-sequence

J7188 is the code for Obizur, a recombinant Factor VIII built on the porcine sequence and billed per IU. It treats acquired hemophilia A, where the patient’s own antibodies attack human Factor VIII. J7191 is the older porcine Factor VIII code, used for Hyate:C, and Obizur doesn’t bill under it.

Medicare pays J7190 at ASP+6%, minus two deductions

Medicare Part B pays J7190 at ASP+6% per IU under the buy-and-bill model, per the Medicare Claims Processing Manual (Pub. 100-04, Chapter 17). CMS updates the Average Sales Price every quarter. Across a full prophylaxis course, a small per-IU change adds up to a material difference.

Medicare also adds a clotting factor furnishing fee per IU, which CMS updates each calendar year. Two adjustments then bring the final payment below the published rate:

• Sequestration: a 2% sequestration reduction applies to Medicare’s payment amount.
• Coinsurance and deductible: Medicare pays 80% of the allowed amount after the Part B deductible. The patient or a supplemental insurer covers the remaining 20%.

Pull the current payment limit from the CMS ASP pricing files before you quote a rate. Medicare Advantage plans set their own payment methods and aren’t bound to the Part B rate.

The NDC has to match the vial you used

State Medicaid programs and many commercial payers require the 11-digit NDC of the product administered alongside J7190. Medicare Part B generally does not. Where a payer requires it, a claim without a valid NDC fails technical edits before medical review.

On a CMS-1500 paper claim, the NDC goes in the shaded area of box 24 with the N4 qualifier. On an 837P electronic claim, it goes in loop 2410. Use the 5-4-2 format (manufacturer-product-package) and keep the leading zeros.

Three NDC mistakes cause most technical denials on J7190 claims:

• Reporting the NDC for the product ordered rather than the product dispensed. Use the NDC from the label of the vial you administered.
• Leaving out the quantity and unit qualifier beside the NDC. Report the quantity administered with the right qualifier.
• Reusing a saved NDC after the manufacturer moves the product to a new NDC.

JW and JZ apply when the product comes in single-dose packaging

CMS made the JZ modifier mandatory on Medicare claims for drugs from single-dose containers on July 1, 2023 (CMS CR 13056, MM13056).

The rule applies when the product is supplied in a single-dose container or single-use package. Claims for single-dose or single-use J7190 products must carry JW or JZ, or Medicare edits can return them.

Place of service changes who bills and how

The place of service (POS) code on a J7190 claim sets the payment rate and the billing route. CMS checks the billed POS against the type of provider on the claim, so a mismatch is an easy audit find.

Home self-infusion is the setting that trips teams up. Under Medicare Part B, J7190 for home use is billed by the supplier or provider furnishing the factor. That may be a specialty pharmacy, a hemophilia treatment center or the ordering physician, depending on the arrangement.

Medicaid rules vary by state, and some states route home infusion through managed care plans with their own prior authorization.

Prior authorization depends on the payer, not the code

Medicare Part B fee-for-service doesn’t currently require prior authorization for J7190. Medicare Advantage plans commonly do, and most commercial plans and Medicaid programs want it before the first dispensing.

A J7190 prior authorization request usually needs:

• A confirmed hemophilia A diagnosis with ICD-10-CM D66 and a factor activity level (below 1% for severe, 1–5% for moderate)
• The body weight used for the dose calculation
• A prescriber statement of prophylaxis or on-demand intent
• A treatment plan with dosing frequency and target factor levels
• The NDC of the specific product requested

A missing authorization is among the costliest J7190 denials, because the fix often means a retrospective appeal. Confirm whether the authorization covers refills as well as the first supply, and put the PA number on every claim. Solid denial management workflows catch a lapsed authorization before the claim goes out.

D66 is the diagnosis most J7190 claims carry

The diagnosis on a J7190 claim has to match both the patient’s condition and the product’s labeled indication. For most claims that means D66, hereditary Factor VIII deficiency. A code the product isn’t approved for triggers a medical necessity denial, even when the HCPCS code and units are right.

Von Willebrand disease claims usually involve a complex product rather than J7190. Those products bill under J7186 or J7187, so check the code before you pair a vWD diagnosis with J7190.

A worked example: One prophylaxis infusion, from order to claim

Here’s how one illustrative claim moves. A 70 kg adult with severe hemophilia A is on prophylaxis with Koate. The order targets a 30% rise, so the formula gives 1,050 IU.

1. Order. The prescriber documents the weight, the 30% target, the product and the dosing schedule.
2. Dispense. The pharmacy picks vials to cover the dose and records each vial’s NDC.
3. Administer. The nurse infuses 1,050 IU and records the IUs given, the lot numbers and any amount discarded.
4. Code. The biller enters J7190 with 1,050 units, D66 first, then Z79.899. JW or JZ follows the wastage record where the payer applies the rule.
5. Submit. The 837P carries the NDC in loop 2410 with its N4 qualifier and quantity, plus the PA number.
6. Reconcile. The remittance comes back, and any denial code is matched to the claim line before the next infusion is billed.

Most problems show up between steps 3 and 4. When the infusion note and the charge disagree on IUs, the claim either underbills or fails an audit later.

Before you submit a J7190 claim: A quick checklist

• The product’s source is human plasma-derived, not recombinant, porcine-sequence or a FVIII/VWF complex.
• Units equal the IUs in the administration record, not the vial count.
• The NDC matches the vial label you used and is in 5-4-2 format, where the payer asks for one.
• JW or JZ is on the line for single-dose or single-use products, with wastage recorded separately.
• The diagnosis matches the product’s labeled indication, usually D66.
• The PA number is on the claim, and the authorized IU total covers this dispensing.
• The POS matches the provider type billing the claim.

Common J7190 denials and how to prevent them

J7190 claims get denied for predictable, fixable reasons. Clotting factor billing has been an Office of Inspector General (OIG) Work Plan target, so payers run tight edits. The table maps each denial to its cause and the fix.

Reading medical billing denial codes alongside the CARC codes on your remittances shows the patterns behind repeat denials. When the same code recurs across several J7190 claims in a month, fix the process rather than appealing claim by claim.

Documentation that holds up in a J7190 audit

An audit of a J7190 claim asks the record to support the product, the dose and the diagnosis billed. Hemophilia treatment centers (HTCs) are the main billers of this code. MAC Local Coverage Determinations commonly expect these elements:

• A lab report showing the Factor VIII activity level and its date
• A prescriber order with the product name, dose in IUs, body weight used and infusion frequency
• An administration record with the IUs given, lot number, NDC and date
• Wastage documentation whenever JW is used, showing the amount given separately from the amount discarded
• A treatment plan naming prophylaxis or on-demand intent, updated at least once a year
• For home self-infusion, training records for the patient or caregiver plus infusion logs that back up the billed dates

The medical billing workflow for clotting factor differs from most Part B drugs because the dose changes with weight and bleed history. Static order sets that don’t reflect the IUs actually given leave billed units you can’t reconcile with the chart.

Prophylaxis vs on-demand: Same code, different paperwork

J7190 is the same code whether the infusion is prophylactic or treats an acute bleed. The code follows the product, and the units follow the dose given. Treatment intent still matters in three places:

• Diagnosis coding: long-term prophylaxis adds Z79.899 as a secondary code beside D66 to support a preventive schedule.
• Prior authorization: some Medicaid managed care plans run separate pathways, with higher quantities and annual renewal for prophylaxis and per-episode approval for on-demand use.
• Documentation: prophylaxis claims need a treatment plan with frequency and target trough levels. On-demand claims need a record of the bleed that triggered the infusion.

How Pabau keeps J7190 claims moving after the infusion

Billing clotting factor by hand means copying IUs from the infusion note, keying the NDC into the claim and checking each remittance by eye. Every hand-off is a place where a unit count or an NDC drifts.

Pabau, the practice management platform we build, keeps the infusion note, the charge and the claim on one patient record. Its denial-tracking claims software supports electronic 837P claims through Claim.MD. It also posts electronic remittance advice back into the workflow.

So when a J7190 line comes back denied, your billing team sees the reason against the original claim. You correct it from the record instead of rebuilding it from paper.

Bill clotting factor claims from one record

Pabau supports electronic 837P claims through Claim.MD and posts ERA remittances back into your workflow. See how it handles high-value drug claims like J7190.

Book a demo

Conclusion

J7190 rewards one habit above the rest. Confirm the product source on the vial before you pick the code. A recombinant, porcine-sequence or complex product billed as J7190 fails however clean the rest of the claim is.

After that, the IU count and the NDC carry the claim. Tie the billed units to the administration record, and keep the NDC tied to the vial you opened. Then most denials become rare process fixes instead of weekly appeals.

Book a demo to see how Pabau links each infusion record to its claim and remittance, so clotting factor billing stops depending on re-keyed numbers.

Continue your research

Need a full picture of how clearinghouse billing works? Medical claims clearinghouse guide explains how payers, clearinghouses, and providers exchange claim data electronically.

Getting recurring claim rejections? Clean claim submission checklist covers the formatting and data requirements that prevent technical rejections before a claim reaches payer adjudication.

Dealing with payer denials after submission? How Claim.MD works with Pabau outlines how automated denial identification and ERA posting reduce the time between denial and correction.

Frequently asked questions